Details of the Drug

General Information of Drug (ID: DMYRX8B)

Drug Name
Ardeparin
Synonyms
Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
Indication
Disease Entry ICD 11 Status REF
Deep vein thrombosis BD71 Approved [1]
Venous thrombosis BA43 Approved [2]
Thrombosis DB61-GB90 Phase 3 [3]
Venous thromboembolism BD72 Phase 3 [4]
Therapeutic Class
Anticoagulants
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1134.9
Logarithm of the Partition Coefficient (xlogp) -10.8
Rotatable Bond Count (rotbonds) 21
Hydrogen Bond Donor Count (hbonddonor) 15
Hydrogen Bond Acceptor Count (hbondacc) 38
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 3.3 hours [5]
Metabolism
The drug is metabolized via the liver []
Chemical Identifiers
Formula
C26H42N2O37S5
IUPAC Name
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
Canonical SMILES
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
InChI
InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
InChIKey
HTTJABKRGRZYRN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
772
CAS Number
9005-49-6
DrugBank ID
DB00407
TTD ID
D01ZJK
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Antithrombin-III (ATIII) TT4QPUL ANT3_HUMAN Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [7]
Antithrombin-III (SERPINC1) OTDFATG0 ANT3_HUMAN Gene/Protein Processing [8]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [9]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [10]
Bone morphogenetic protein receptor type-1A (BMPR1A) OTQOA4ZH BMR1A_HUMAN Gene/Protein Processing [10]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [11]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Gene/Protein Processing [12]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [13]
Catalase (CAT) OTHEBX9R CATA_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ardeparin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Ardeparin and Ardeparin. Coronary thrombosis [BA43] [15]
Coadministration of a Drug Treating the Disease Different from Ardeparin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cilostazol DMZMSCT Major Increased risk of bleeding by the combination of Ardeparin and Cilostazol. Arterial occlusive disease [BD40] [15]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Ardeparin and Pentosan polysulfate. Chronic pain [MG30] [16]
Ketoprofen DMRKXPT Major Increased risk of bleeding by the combination of Ardeparin and Ketoprofen. Chronic pain [MG30] [17]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Ardeparin and Levomilnacipran. Chronic pain [MG30] [18]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Ardeparin and Anisindione. Coagulation defect [3B10] [19]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Ardeparin and Regorafenib. Colorectal cancer [2B91] [20]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Ardeparin and Intedanib. Colorectal cancer [2B91] [21]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Ardeparin and Drospirenone. Contraceptive management [QA21] [22]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Ardeparin and Danaparoid. Deep vein thrombosis [BD71] [15]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Ardeparin and Rivaroxaban. Deep vein thrombosis [BD71] [15]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Ardeparin and Sertraline. Depression [6A70-6A7Z] [18]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Ardeparin and Fluoxetine. Depression [6A70-6A7Z] [18]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Ardeparin and Vilazodone. Depression [6A70-6A7Z] [18]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Ardeparin and Paroxetine. Depression [6A70-6A7Z] [18]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Ardeparin and Vortioxetine. Depression [6A70-6A7Z] [18]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Ardeparin and Duloxetine. Depression [6A70-6A7Z] [18]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Ardeparin and Milnacipran. Depression [6A70-6A7Z] [18]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Ardeparin and Escitalopram. Depression [6A70-6A7Z] [18]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Ardeparin and Desvenlafaxine. Depression [6A70-6A7Z] [18]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Ardeparin and Heme. Discovery agent [N.A.] [23]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Ardeparin and Apigenin. Discovery agent [N.A.] [24]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Ardeparin and PMID28870136-Compound-49. Discovery agent [N.A.] [25]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Ardeparin and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [18]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Ardeparin and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [26]
Mefenamic acid DMK7HFI Major Increased risk of bleeding by the combination of Ardeparin and Mefenamic acid. Female pelvic pain [GA34] [17]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Ardeparin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [20]
Spironolactone DM2AQ5N Moderate Increased risk of hyperkalemia by the combination of Ardeparin and Spironolactone. Heart failure [BD10-BD1Z] [20]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Ardeparin and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [27]
Aliskiren DM1BV7W Moderate Increased risk of hyperkalemia by the combination of Ardeparin and Aliskiren. Hypertension [BA00-BA04] [28]
Captopril DM458UM Moderate Increased risk of hyperkalemia by the combination of Ardeparin and Captopril. Hypertension [BA00-BA04] [29]
TAK-491 DMCF6SX Moderate Increased risk of hyperkalemia by the combination of Ardeparin and TAK-491. Hypertension [BA00-BA04] [29]
Dipyridamole DMXY30O Major Increased risk of bleeding by the combination of Ardeparin and Dipyridamole. Hypertension [BA00-BA04] [15]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Ardeparin and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [30]
Meclofenamic acid DM05FXR Major Increased risk of bleeding by the combination of Ardeparin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [31]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Ardeparin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [32]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Ardeparin and Acalabrutinib. Mature B-cell lymphoma [2A85] [33]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Ardeparin and Ibrutinib. Mature B-cell lymphoma [2A85] [34]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Ardeparin and Ponatinib. Mature B-cell lymphoma [2A85] [35]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Ardeparin and Panobinostat. Multiple myeloma [2A83] [36]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Ardeparin and Fedratinib. Myeloproliferative neoplasm [2A20] [37]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Ardeparin and Ruxolitinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Ardeparin and Dasatinib. Myeloproliferative neoplasm [2A20] [38]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Ardeparin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [16]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Ardeparin and Prasugrel. Myocardial infarction [BA41-BA43] [15]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Ardeparin and Vorapaxar. Myocardial infarction [BA41-BA43] [15]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Ardeparin and Tirofiban. Myocardial infarction [BA41-BA43] [15]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Ardeparin and Sibutramine. Obesity [5B80-5B81] [39]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Ardeparin and Dexfenfluramine. Obesity [5B80-5B81] [18]
Diclofenac DMPIHLS Major Increased risk of bleeding by the combination of Ardeparin and Diclofenac. Osteoarthritis [FA00-FA05] [17]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Ardeparin and Nepafenac. Osteoarthritis [FA00-FA05] [26]
Naproxen DMZ5RGV Major Increased risk of bleeding by the combination of Ardeparin and Naproxen. Osteoarthritis [FA00-FA05] [17]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Ardeparin and MK-4827. Ovarian cancer [2C73] [20]
Aspirin DM672AH Major Increased risk of bleeding by the combination of Ardeparin and Aspirin. Pain [MG30-MG3Z] [31]
Etodolac DM6WJO9 Major Increased risk of bleeding by the combination of Ardeparin and Etodolac. Pain [MG30-MG3Z] [17]
Diflunisal DM7EN8I Major Increased risk of bleeding by the combination of Ardeparin and Diflunisal. Pain [MG30-MG3Z] [17]
Ibuprofen DM8VCBE Major Increased risk of bleeding by the combination of Ardeparin and Ibuprofen. Pain [MG30-MG3Z] [17]
Nabumetone DMAT2XH Major Increased risk of bleeding by the combination of Ardeparin and Nabumetone. Pain [MG30-MG3Z] [17]
Piroxicam DMTK234 Major Increased risk of bleeding by the combination of Ardeparin and Piroxicam. Pain [MG30-MG3Z] [17]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Ardeparin and Choline salicylate. Postoperative inflammation [1A00-CA43] [40]
Ketorolac DMI4EL5 Major Increased risk of bleeding by the combination of Ardeparin and Ketorolac. Postoperative inflammation [1A00-CA43] [17]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Ardeparin and Bromfenac. Postoperative inflammation [1A00-CA43] [26]
Epoprostenol DMUTYR2 Major Increased risk of bleeding by the combination of Ardeparin and Epoprostenol. Pulmonary hypertension [BB01] [15]
Iloprost DMVPZBE Major Increased risk of bleeding by the combination of Ardeparin and Iloprost. Pulmonary hypertension [BB01] [15]
Salsalate DM13P4C Moderate Increased risk of bleeding by the combination of Ardeparin and Salsalate. Rheumatoid arthritis [FA20] [41]
Meloxicam DM2AR7L Major Increased risk of bleeding by the combination of Ardeparin and Meloxicam. Rheumatoid arthritis [FA20] [17]
Sulindac DM2QHZU Major Increased risk of bleeding by the combination of Ardeparin and Sulindac. Rheumatoid arthritis [FA20] [17]
Oxaprozin DM9UB0P Major Increased risk of bleeding by the combination of Ardeparin and Oxaprozin. Rheumatoid arthritis [FA20] [17]
Flurbiprofen DMGN4BY Major Increased risk of bleeding by the combination of Ardeparin and Flurbiprofen. Rheumatoid arthritis [FA20] [17]
Fenoprofen DML5VQ0 Major Increased risk of bleeding by the combination of Ardeparin and Fenoprofen. Rheumatoid arthritis [FA20] [17]
Tolmetin DMWUIJE Major Increased risk of bleeding by the combination of Ardeparin and Tolmetin. Rheumatoid arthritis [FA20] [17]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Ardeparin and Curcumin. Solid tumour/cancer [2A00-2F9Z] [42]
Warfarin DMJYCVW Major Increased risk of bleeding by the combination of Ardeparin and Warfarin. Supraventricular tachyarrhythmia [BC81] [15]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Ardeparin and Plicamycin. Testicular cancer [2C80] [15]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Ardeparin and Caplacizumab. Thrombocytopenia [3B64] [36]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Ardeparin and Apixaban. Thrombosis [DB61-GB90] [15]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Ardeparin and Cangrelor. Thrombosis [DB61-GB90] [43]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Ardeparin and Brilinta. Thrombosis [DB61-GB90] [15]
Clopidogrel DMOL54H Major Increased risk of bleeding by the combination of Ardeparin and Clopidogrel. Thrombosis [DB61-GB90] [15]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Ardeparin and Cabozantinib. Thyroid cancer [2D10] [44]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Ardeparin and Tolbutamide. Type 2 diabetes mellitus [5A11] [45]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Ardeparin and Betrixaban. Venous thromboembolism [BD72] [37]
⏷ Show the Full List of 81 DDI Information of This Drug

References

1 Pharmacologic profile of certoparin. Expert Opin Investig Drugs. 1999 Mar;8(3):315-27.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6811).
3 Clinical pipeline report, company report or official report of Emisphere Technologies Inc.
4 Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity. Mediators Inflamm. 2000;9(2):85-91. doi: 10.1080/096293500411541.
8 Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995 Apr 1;91(7):1929-35. doi: 10.1161/01.cir.91.7.1929.
9 Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res. 2001 Dec;11(4):311-5. doi: 10.1038/sj.cr.7290101.
10 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
11 Serum acute phase protein concentrations after hysterectomy with and without low-molecular-weight heparin thrombosis prophylaxis. Acta Obstet Gynecol Scand. 2005 Aug;84(8):752-5. doi: 10.1111/j.0001-6349.2005.00722.x.
12 Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. Curr Cancer Drug Targets. 2010 Mar;10(2):229-41. doi: 10.2174/156800910791054176.
13 Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006 Apr;12(4):237-43. doi: 10.1093/molehr/gal026. Epub 2006 Mar 23.
14 Heparin reduces oxidative stress in the postoperative period. Med Sci Monit. 2002 Sep;8(9):CR657-60.
15 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
16 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
17 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
18 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
19 Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
22 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
23 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
24 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
25 Canadian Pharmacists Association.
26 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
27 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
28 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
29 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
30 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
31 Product Information. Lovenox (enoxaparin). Rhone-Poulenc Rorer, Collegeville, PA.
32 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
33 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
35 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
36 Cerner Multum, Inc. "Australian Product Information.".
37 Product Information. Fragmin (dalteparin). Pharmacia and Upjohn, Kalamazoo, MI.
38 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
39 Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8. [PMID: 8826562]
40 Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
41 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
42 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
43 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
44 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
45 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]